On February 5, 2026, SpyGlass Pharma, Inc., a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by SpyGlass Pharma, are expected to be approximately $150 million. Wilson Sonsini Goodrich & Rosati advised SpyGlass Pharma on the transaction.

SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.

The Wilson Sonsini team that advised SpyGlass Pharma includes:

Corporate
Dan Koeppen
Jennifer Fang
Rob Wernli
Ben Capps
Tamara Brightwell
Bridget Balisy
Dante Matera

Technology Transactions
Ian Edvalson
Lowell Segal
Alex DeLaney

Delaware Law
Ryan Greecher
Adrian Broderick
Sarah Hand

Employee Benefits and Compensation
Megan Schilling
Dani Nazemian
Kristen Stidham
Emma Wilcox

Employment Law
Matt Gorman

Regulatory
Eva Yin

Tax
Myra Sutanto Shen
Rob Sherrill

For more information, please see the company’s news release.